Tarsus Pharmaceuticals Reports Q3 Revenue Beat Amid Significant GAAP EPS Miss
Tarsus Pharmaceuticals (TARS) reported third-quarter financial results characterized by a significant divergence between top-line growth and bottom-line profitability. The company achieved revenue of $194.5 million, representing a 63.9% increase year-over-year and slightly exceeding market expectations by $3.72 million. However, the company reported a substantial GAAP loss, with earnings per share (EPS) of -$14.40, missing analyst estimates by $10.38. Despite the heavy losses, Tarsus maintains a strong liquidity position, reporting $309.6 million in cash, cash equivalents, and marketable securities as of September 30, 2026.
Tickers: $TARS
Topics: cash position earnings miss financial results revenue beat